299397-13-0

Basic information

• Product Name: 4(1H)-Pyrimidinone,2-[(1R)-1-hydroxyethyl]-
• Synonyms: 4(1H)-Pyrimidinone,2-[(1R)-1-hydroxyethyl]-;4(1H)-Pyrimidinone, 2-[(1R)-1-hydroxyethyl]- (9CI)
• CAS NO: 299397-13-0
• Molecular Formula: C6H8N2O2
• Molecular Weight: 140.13992
• Product Categories: ACETYLGROUP;PYRIMIDINE
• Mol File: 299397-13-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4(1H)-Pyrimidinone,2-[(1R)-1-hydroxyethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-Pyrimidinone,2-[(1R)-1-hydroxyethyl]-(299397-13-0)
• EPA Substance Registry System: 4(1H)-Pyrimidinone,2-[(1R)-1-hydroxyethyl]-(299397-13-0)

Safety Data

• Hazardous Substances Data: 299397-13-0(Hazardous Substances Data)

Upstream product

• 91431-03-7 lactamidine 
• 34780-29-5 3-oxo-propionic acid ethyl ester 
• 89799-34-8 2-hydroxypropanimidamide hydrochloride 

Downstream Products

• 475486-89-6 2-acetylpyrimidin-4(3H)-one 

Relevant articles and documents

2- (PIPERIDIN-1-YL) -4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. Ring A is selected from formula (a), (b) or (b'):

Compounds for treating and preventing diabetic complications

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R is as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.